Navigation Links
BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
Date:11/19/2013

BETHLEHEM, Pa., Nov. 19, 2013 /PRNewswire/ -- Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), has been contracted by BHR Pharma to develop an in-field nasally applied formulation of Progesterone for traumatic brain injury (TBI).  BHR is pioneering this treatment and is well into their study, SyNAPSe® (Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries), a global, Phase 3, multi-center pivotal trial in severe TBI using a parenteral formulation that was independently developed.  According to Mark Mitchnick, MD, Particle Sciences' CEO, "Particle Sciences focuses on formulation design and manufacturing.  Our clients often face challenging delivery issues so the dosage forms we work with frequently require a high level of engineering and the simplification of complex formulation challenges to commercially viable products.  In this case, the challenge was achieving rapid onset under conditions of true duress, trauma.  The product had to be versatile and durable.  BHR are world leaders in this therapeutic approach and working with their technical team we have been able to design a dosage form that meets their needs.  We look forward to helping BHR bring this very important product into the clinic and through to commercialization."        

Particle Sciences is an integrated pharmaceutical CDMO.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and ma
'/>"/>

SOURCE Particle Sciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Maximizing Production Capacity for Growth - Finding 5% for Pharmaceutical or Biotech Companies through Facility Optimization, a New Life Science Webinar from Xtalks
2. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
3. IPISC announces IP insurance for the Biotechnology/Pharma Industry
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
6. SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
7. HealthEconomics.Com Distinguished Again as Top Influencer at the International Society for Pharmacoeconomics and Outcomes Research 16th Annual European Congress in Dublin
8. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
9. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
10. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
11. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... , May 28, 2015 Natera, Inc., ... a study published in Ultrasound in Obstetrics ... polymorphism (SNP)-based non-invasive prenatal test (NIPT) can identify ... A study based upon data ... pregnancies occur in about 1 in 1,000 pregnancies, ...
(Date:5/28/2015)... N.J. , May 28, 2015  PDS ... a cancer immunotherapy treatment targeting HPV-16, has generated ... Currently, pre-cervical cancer is treated by ... a simple and effective non-surgical alternative. Results show ... mechanisms (T-cells) to recognize, target, and kill precancerous ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2GenVec To Present At The Jefferies Healthcare Conference 2
... , CARLISLE, Mass., Aug. 5 ... launch of a fully integrated microarray solution platform. ... biochips and advanced microarray instrument systems, in collaboration ... and instrumentation software, now offers a platform that ...
... , CHICAGO, Aug. 5 Advanced ... it will host a conference call and webcast discussing the Company,s ... a.m. (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, ... present an update on the Company. A press release reporting the ...
... Framework Reaffirmed , Shire plc (LSE: SHP, NASDAQ: SHPGY ) the global specialty,biopharmaceutical company, announces results for the ... ... Q2 2009(1), Product sales ... -21%, Product sales (excluding ADDERALL XR) $491 million ...
Cached Biology Technology:CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 2CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 3Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 3Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 4Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 5Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 6Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 7Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 8Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 9Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 10Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 11Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 12Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 13Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 14Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 15Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 16Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 17Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 18Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 19Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 20Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 21Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 22Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 23Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 24Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 25Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 26Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 27Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 28Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 29Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 30Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 31Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 32Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 33
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Ky. The University of Louisville today announced that ... into a license and research collaboration agreement with Novartis ... the potential to help transplant patients avoid taking anti-rejection ... for treatment of other diseases. The University ...
... Boston University School of Medicine (BUSM) suggests that epigenetics may ... relapse of cancer. The findings are published online in Volume ... The term epigenetics refers to the external modifications ... do not change the DNA sequence, but instead, they affect ...
... MA New insights into how human cytomegalovirus ... with infection spreads from pregnant mother to fetus ... translational researchers an exciting new avenue for investigation ... interventions. Using next generation sequencing and population genetic ...
Cached Biology News:University of Louisville researchers sign global licensing agreement 2University of Louisville researchers sign global licensing agreement 3BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy 2Research points to potential window for treating CMV and preventing mother-to-child transmission 2Research points to potential window for treating CMV and preventing mother-to-child transmission 3
... Designed to meet the ... this animal component-free medium supports ... high cell densities, while maintaining ... recombinant protein production using the ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z36,327-8) ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: